Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study)
Sponsor: Beijing Anzhen Hospital
This NA trial investigates Acute Coronary Syndrome and Angina, Stable and is currently ongoing. Beijing Anzhen Hospital leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting NA
-
Nov 2024 — Jan 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Oct 2023 — Jul 2024 [monthly]
Recruiting NA
▶ Show 7 earlier versions
-
Dec 2021 — Oct 2023 [monthly]
Recruiting NA
-
Jan 2021 — Dec 2021 [monthly]
Recruiting NA
Phase: PHASE4 → NA
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Anzhen Hospital
For direct contact, visit the study record on ClinicalTrials.gov .